Hiperplasia Endometrium

01Pathophysiology

The endometrium is an estrogen-responsive tissue. Under normal physiology, estrogen drives proliferation of endometrial glands during the follicular phase, and progesterone (secreted by the corpus luteum after ovulation) stabilizes and differentiates the endometrium during the secretory phase. When ovulation fails to occur or when exogenous estrogen is administered without progesterone, this regulatory counterbalance is lost. The endometrium is exposed to continuous, unchecked estrogen stimulation, which drives excessive glandular proliferation. This is the core concept: unopposed estrogen leads to endometrial hyperplasia.

The clinical consequence is predictable. A thickened, unstable endometrium sheds irregularly, producing abnormal uterine bleeding. The glands become crowded, dilated, and architecturally disorganized. Over time, if the estrogenic stimulus persists, the glandular epithelium may develop cytologic atypia, nuclear enlargement, loss of polarity, and prominent nucleoli. This atypical hyperplasia is considered a premalignant lesion with a well-documented progression rate to endometrioid endometrial carcinoma.

This is why the exam connects conditions of chronic anovulation (such as PCOS) and exogenous estrogen exposure (such as tamoxifen acting as an estrogen agonist on the endometrium, or estrogen-only hormone replacement therapy) directly to endometrial hyperplasia. The same logic applies to obesity: adipose tissue contains aromatase, which converts adrenal androgens to estrone, creating a state of peripheral hyperestrogenism. Similarly, granulosa cell tumors of the ovary are functional tumors that secrete estrogen autonomously.

02Classification and Clinical Manifestation

The older WHO 1994 classification (simple vs. complex, with or without atypia) has been replaced by the WHO 2014/EIN (Endometrial Intraepithelial Neoplasia) system, which is the framework tested on modern exams.

The clinical manifestation across both types is similar and revolves around abnormal uterine bleeding:

03Diagnostic Workup

The evaluation of abnormal uterine bleeding begins with determining the clinical context. In a postmenopausal woman with any vaginal bleeding, the first step is transvaginal ultrasound. If the endometrial stripe measures >4 mm, the next step is tissue sampling, most commonly via office endometrial biopsy (pipelle aspiration). This is a quick, outpatient procedure that provides histologic diagnosis without the need for anesthesia.

If the biopsy returns non-diagnostic (insufficient tissue, which happens in approximately 10-15% of cases) or if bleeding persists despite a benign biopsy result, the next step is hysteroscopy with directed biopsy or formal D&C. This is the gold standard because it allows the clinician to visualize the entire uterine cavity, identify focal lesions such as polyps that a blind pipelle might miss, and obtain targeted tissue samples.

In premenopausal women, the threshold for biopsy is based on risk factors rather than endometrial thickness alone. Women over 35 with abnormal bleeding, or younger women with significant risk factors (obesity, chronic anovulation, tamoxifen use), should undergo endometrial biopsy. The endometrial thickness cutoff of >4 mm does not apply reliably in premenopausal patients because normal proliferative-phase endometrium can measure 8-14 mm.

One important exam point: a normal endometrial thickness on ultrasound in a postmenopausal woman (<4 mm) has a high negative predictive value for endometrial carcinoma and generally does not require biopsy. However, if the patient has recurrent postmenopausal bleeding, biopsy should still be considered regardless of thickness.

04Management and Treatment

The first decision point is atypia. This is the most important prognostic discriminator and the primary driver of management decisions.

For hyperplasia without atypia, the condition is benign and the progression risk to carcinoma is very low. The goal is to counteract the unopposed estrogen with progestin therapy. The levonorgestrel-releasing IUD is the preferred method because it delivers high local concentrations of progestin directly to the endometrium while minimizing systemic side effects. Oral progestins are an acceptable alternative. The patient should undergo surveillance biopsy at 3-6 months to document histologic regression. If the endometrium normalizes, the progestin therapy should continue for a minimum of 6-12 months. Simultaneously, the underlying cause of unopposed estrogen should be addressed: weight loss counseling for obese patients, cycle regulation in PCOS, and discontinuation or modification of exogenous estrogen.

For atypical hyperplasia, the calculus changes entirely. The concurrent carcinoma rate is so high (up to 40-50% in some surgical series) that total hysterectomy is the definitive recommendation for women who have completed childbearing. This is not an aggressive approach; it is appropriate because the biopsy may be undersampling a coexisting well-differentiated carcinoma.

For the young patient with atypia who desires fertility, high-dose progestin therapy is offered as a temporizing measure, but the patient must understand that this is not curative. Close surveillance with repeat biopsy every 3 months is mandatory. If regression is confirmed, the patient should be encouraged to conceive as soon as possible, ideally with the help of reproductive endocrinology if needed. After childbearing, hysterectomy remains recommended.

Contraindications and considerations: Progestin therapy should be used with caution in patients with active thromboembolic disease or severe hepatic dysfunction. In such cases, the levonorgestrel IUD may be preferred over systemic oral progestins due to its predominantly local action.

05Differential Diagnosis and Distractors

06Traps and High-Yield Pearls

The single most tested concept in endometrial hyperplasia is the distinction between with and without atypia, because this distinction drives the entire management algorithm. Students frequently default to "give progestins" for all forms of hyperplasia, missing that atypical hyperplasia in a woman who has completed childbearing warrants hysterectomy, not prolonged medical therapy. The concurrent carcinoma rate of 25-50% in atypical hyperplasia is the number that justifies this surgical approach.

A common trap involves the postmenopausal bleeding vignette. The test-writer will present a postmenopausal woman with vaginal bleeding and a thickened endometrial stripe. The student must recognize that the next step is tissue sampling (endometrial biopsy), not repeating the ultrasound, ordering tumor markers, or starting empiric progestins. Ultrasound identifies who needs a biopsy; it does not replace one.

Another frequently tested scenario is the PCOS patient with prolonged amenorrhea who then presents with heavy breakthrough bleeding. Students may focus on the PCOS workup (testosterone, DHEA-S, 17-hydroxyprogesterone) and forget that the prolonged anovulation has created an unopposed estrogen state requiring endometrial evaluation. If the patient is over 35 or has persistent abnormal bleeding, endometrial biopsy is indicated regardless of PCOS status.

Watch for the tamoxifen vignette. Tamoxifen is an estrogen receptor antagonist in breast tissue but acts as an agonist on the endometrium. A breast cancer patient on tamoxifen who develops vaginal bleeding should receive the same workup as any other patient with suspected endometrial pathology: ultrasound followed by biopsy.

Finally, do not confuse the endometrial thickness cutoff. The >4 mm threshold applies only to postmenopausal women. Using this cutoff in a premenopausal patient is a common error, since a normal proliferative endometrium can be significantly thicker. In premenopausal patients, the decision to biopsy is based on clinical risk factors and the nature of the bleeding, not on endometrial thickness alone.